Progress in prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage

doi:10.3877/cma.j.issn.2095-9141.2018.05.012

Abstract

Abstract:

Cerebral vasospasm (CVS) caused by subarachnoid hemorrhage (SAH) is always a knotty problem in clinical treatment, which causes secondary cerebral ischemia and seriously affects the prognosis of patients. At present, most of the treatment comes from the experience of the use of drugs. This article reviews the clinical prevention and treatment of CVS.

Key words: Subarachnoid hemorrhage, Cerebral vasospasm, Medication

Hao Zhao, Wenlong Pan, Ruxiang Xu. Progress in prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2018, 04(05): 304-307.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2018.05.012

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2018/V04/I05/304

References 43

[1]	Wong GKC, Tam YYW, Zhu XL, et al. Incidence and mortality of spontaneous subarachnoid hemorrhage in Hong Kong from 2002 to 2010[J]. World Neurosurg, 2014, 81(3): 552-556.
[2]	Dababneh H, Guerrero W, Mehta S, et al. Possible role of Eptifibatide drip in-patient with aneurysmal subarachnoid hemorrhage in vasospasm prevention[J]. J Vasc Interv Neurol, 2014, 7(3): 8-13.
[3]	陈博文，成杰，田华,等.蛛网膜下腔出血后脑血管痉挛的研究进展[J].华北煤炭医学院学报, 2011, 13(3): 319-321.
[4]	贺西亮，潘源，卢佩林,等.动脉内超选滴注法舒地尔治疗症状性脑血管痉挛疗效分析[J].介入放射学杂志, 2015, 24(10): 846-848.
[5]	Eseonu CI, ReFaey K, Geocadin RG, et al. Postoperative cerebral vasospasm following transsphenoidal pituitary adenoma surgery[J]. World Neurosurg, 2016, (92): 7-14.
[6]	付超，赵从海.动脉瘤性蛛网膜下腔出血后早期脑损伤病理生理的研究进展[J].中华神经医学杂志, 2013, 12(10): 1073-1076.
[7]	Liu GJ, Wang ZJ, Wang YF, et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage[J]. Eur J Clin Pharmacol, 2012, 68(2): 131-139.
[8]	王玉妹，唐思魏，石广志,等.蛛网膜下腔出血后迟发性脑血管痉挛的发病机制和治疗进展[J].中国卒中杂志, 2016, 11(6): 494-500.
[9]	Ni W, Gu YX, Song DL, et al. The relationship between IL-6 in CSF and occurrence of vasospasm after subarachnoid hemorrhage[J]. Acta Neurochir Suppl, 2011, 110(Pt1): 203-208.
[10]	赵旭东，史继新.蛛网膜下腔出血后脑血管痉挛发病机制及治疗的研究进展[J].医学研究生学报, 2010, 23(2): 218-222.
[11]	Brown RJ, Epling BP, Staff I, et al. Polyuria and cerebral vasospasm after aneurysmal subarachnoid hemorrhage[J]. BMC Neurol, 2015, 15(1): 1-7.
[12]	杨位霞，毛蕾蕾，袁慧.蛛网膜下腔出血后迟发性脑血管痉挛的机制[J].中华行为医学与脑科学杂志, 2014, 23(11): 1048-1050.
[13]	林冬，朱占胜，吴明灿.炎性因子在自发性蛛网膜下隙出血后脑血管痉挛中作用的研究进展[J].医学综述, 2012, 18(16): 2560-2561.
[14]	Sepp D, Franz D, Triftshaeuser N, et al. Mobilization of CD133+ progenitor cells in patients with acute cerebral infarction[J]. Plos One, 2014, 9(3): e70796.
[15]	Wang Y, Zhang L, Jia L, et al. Calcitionin gene-related peptide in aerobic exercise induces collateral circulation development in rat ischemia myocardium[J]. Biomed Pharmacother, 2016, 123(82): 561-567.
[16]	Szpecht D, Gadzinowski J, Seremak-Mrozikiewicz A, et al. Role of endothelial nitric oxide synthase and endothelin-1 polymorphism genes with the pathogenesis of intraventricular hemorrhage in preterm infants[J]. Sci Rep, 2017, 22(5): 188-190.
[17]	周建军，官测林，沈东伟,等.破裂颅内动脉瘤夹闭术后症状性脑血管痉挛发生的相关因素研究[J].中外医学研究, 2017, 15(16): 20-21.
[18]	Tam AK, Kapadia A, Ilodigwe D, et al. Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage[J]. J Neurosurg, 2013, 119(1): 198-206.
[19]	中华神经科学会，中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29(6): 379-380.
[20]	常谦，刘俊，岑键昌.改良Fisher分级与破裂动脉瘤患者症状性脑血管痉挛的关系[J].实用心脑肺血管病杂志, 2012, 20(7): 1209-1210.
[21]	谢飞，陈志远，曾家良,等. DSA联合血清SICAM-1评估颅内破裂动脉瘤术后脑血管痉挛的效果[J].中国临床神经外科杂志, 2017, 22(9): 617-618, 622.
[22]	姜大宇，陈晓旭，汪新宇,等.血清MMP-9与动脉瘤性蛛网膜下腔出血脑血管痉挛的相关性研究[J].中国医药指南, 2017, 15(8): 3-4, 5.
[23]	沈佳，陈彬，郑关荣,等.尼莫地平注射液联合参附注射液治疗创伤性蛛网膜下腔出血的临床研究[J].中国临床药理学杂志, 2017, 33(19): 1865-1867.
[24]	陈旭，詹健，张永安,等.法舒地尔对蛛网膜下腔出血后造成脑血管痉挛的临床疗效及安全性分析[J].当代医学, 2017, 23(28): 115-116.
[25]	刘先进，郭春锋.扩容疗法应用于动脉瘤术后脑血管痉挛中的效果研究[J].医药论坛杂志, 2017, 38(7): 83-85.
[26]	Ott S, Jedlicka S, Wolf S, et al. Continuous selective intra-ar-terial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage[J]. Biomed Res Int, 2014, 2014: 970741.
[27]	张深义.丁咯地尔预防蛛网膜下腔出血后脑血管痉挛效果观察及其机制[J].数理医药学杂志, 2017, 30(9): 1343-1344.
[28]	Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect[J]. Arterioscler Thromb Vasc Biol, 2014, 34(9): 2078-2085.
[29]	王鹏，林涛，车海江.瑞舒伐他汀联合法舒地尔对破裂颅内动脉瘤栓塞术后患者DCVS发生率、MCA流速及生活质量的影响[J].解放军医学杂志, 2017, 29(8): 93-96.
[30]	杜延平，李乐军，时忠华,等.长春西汀不同给药途径治疗破裂颅内动脉瘤栓塞术并发脑血管痉挛的疗效安全性对比研究[J].中国药理学通报, 2017, 33(6): 859-862.
[31]	周建宏，陆爻忠，蒋云召,等.早期高压氧治疗颅内动脉瘤破裂栓塞术后脑血管痉挛的临床研究[J].临床合理用药, 2017, 10(13): 16-18.
[32]	杨波，刘曙艳.白介素10联合尼莫地平治疗蛛网膜下腔出血伴脑血管痉挛的临床疗效观察[J].中国民康医学, 2017, 29(12): 19-20.
[33]	Miyaji Y, Yoshimura S, Sakai N, et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan registry[J]. Neurol Med Chir (Tokyo), 2015, 55(3): 241-247.
[34]	唐红宇，梁永，颜建辉,等.依达拉奉联合尼莫地平对动脉瘤性蛛网膜下腔出血患者术后脑血管痉挛的疗效研究[J].肿瘤药学, 2017, 7(3): 324-327.
[35]	李树浩，李东航.尤瑞克林防治蛛网膜下腔出血迟发性脑血管痉挛的临床研究[J].现代诊断与治疗, 2017, 28(5): 866-868.
[36]	杨彬源，陈桂增，王本艳,等.马来酸桂哌齐特联合尼莫地平治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛疗效观察[J].海南医学, 2017, 28(6): 971-973.
[37]	王培明，周立云，连宗德,等.右美托咪定对动脉瘤性蛛网膜下腔出血围介入栓塞手术期血流动力学以及继发脑血管痉挛发生的影响分析[J].中国现代药物应用, 2017, 11(7): 89-91.
[38]	汪子文，桂铮，卢学刚,等.磁导向纳米磁性药物载体对迟发型脑血管痉挛干预的实验研究[J].中国神经外科疾病研究杂志, 2017, 16(4): 293-296.
[39]	张毅，柏鲁宁，张昭,等.脑血疏口服液对兔蛛网膜下腔出血后脑血管痉挛及IL-6、eNOS的影响[J].中西医结合心脑血管疾病杂志, 2017, 15(18): 2257-2259.
[40]	胡艳龙，张洪兵，黄庆,等.清开灵注射液辅助治疗前循环颅内动脉瘤破裂出血术后脑血管痉挛对血清炎性因子、ET-1、NO及NOS的影响[J].现代中西医结合杂志, 2017, 26(27): 3004-3006.
[41]	张宗鹏，张娟，秦永磊,等.补阳还五汤联合尼莫同治疗脑血管造影术中血管痉挛疗效观察[J].世界最新医学信息文摘, 2017, 17(70): 118-122.
[42]	拜锦星，彭绍鹏.疏肝解痉汤加减联合头穴透刺法治疗外伤性蛛网膜下腔出血后脑血管痉挛35例[J].中医研究, 2017, 30(8): 12-15.
[43]	雷靖安，刘志广，刘忠志,等.丁苯酞注射液联合醒脑静注射液对动脉瘤性蛛网膜下腔出血脑血管痉挛患者血清NSE、CRP及FABP水平的影响[J].现代中西医结合杂志, 2017, 26(19): 2143-2146.

Please choose a citation manager

Content to export